Healthcare
Live Price
Offline$16.45
+0.00% today
1Y Change
+151.15%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SanBio Company Limited (SNBIF) is a Healthcare stock with a market cap of $153.74B and listed on OTC. The stock last traded around $16.45 and up 151.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -25.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -25.8%, free cash flow -6.4% with operating margin 0.0% and ROIC -22.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNBIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNBIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNBIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNBIF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.7B
+15.9% YoY
Free Cash Flow
-$6.6B
+11.3% YoY
Revenue Growth
+0.0%
EPS Growth
-25.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
JPY
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -8M | 0 | -15M | -25M | -132M |
| Operating Income | -3.8B | -3.5B | -4.5B | -7.9B | -6.6B |
| EBITDA | -3.8B | -3.5B | -4.5B | -4.6B | -4.4B |
| Net Income | -3.8B | -2.9B | -2.6B | -5.6B | -4.7B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.1B | 2.9B | 4.5B | 6.7B | 4.6B |
| Total Assets | 15.6B | 3.4B | 5.0B | 7.0B | 5.5B |
| Total Liabilities | 2.0B | 1.7B | 2.3B | 2.6B | 3.5B |
| Shareholder Equity | 13.6B | 1.8B | 2.8B | 4.4B | 2.0B |
| Total Debt | 1.2B | 397M | 665M | 933M | 2.5B |
| Net Debt | -13.8B | -2.5B | -3.8B | -5.8B | -2.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6.5B
+11.9% YoY
Capital Expenditures
56M
-600.7% YoY
Free Cash Flow
6.6B
+11.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-88.9%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.